Decision

Biogen Canada Inc. v. Taro Pharmaceuticals Inc., 2019 FC 942 (Fampridine*)

Proth. Tabib - 2019-07-15

Read full decision. Automatically generated summary:

The Defendants in each of the above-mentioned actions brought a single motion to rule on objections and to compel answers to questions asked in the context of the follow-up round of their common examinations for discovery of the Plaintiffs’ representatives. The Court ruled on most of the objections from the bench at the hearing, but reserved its decision in respect of two categories of questions. These questions essentially seek production of transcripts of depositions given by certain witnesses in the course of judicial and administrative proceedings in the United States.

Decision relates to:

  • T-1163-18 - BIOGEN CANADA INC ET AL v. TARO PHARMACEUTICALS INC
  • T-1416-18 - BIOGEN CANADA INC. and OTHERS v. APOTEX INC.
  • T-220-19 - BIOGEN CANADA INC. et al. v. PHARMASCIENCE INC.

 

Canadian Intellectual Property